ASP Isotopes (NASDAQ:ASPI) Announces Earnings Results

ASP Isotopes (NASDAQ:ASPI) announced its earnings results on Wednesday. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.05), Zacks reports. ASP Isotopes had a negative net margin of 2,181.62% and a negative return on equity of 239.22%.

ASP Isotopes Stock Down 1.7%

ASPI stock traded down $0.13 on Wednesday, hitting $7.50. 4,685,866 shares of the company’s stock were exchanged, compared to its average volume of 4,326,196. The firm has a 50 day moving average price of $9.62 and a two-hundred day moving average price of $8.80. ASP Isotopes has a 12-month low of $3.65 and a 12-month high of $14.49. The stock has a market cap of $700.58 million, a P/E ratio of -5.91 and a beta of 3.28. The company has a debt-to-equity ratio of 3.53, a quick ratio of 14.56 and a current ratio of 14.72.

Insiders Place Their Bets

In related news, Director Duncan Moore sold 75,000 shares of ASP Isotopes stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $9.28, for a total transaction of $696,000.00. Following the completion of the sale, the director owned 994,553 shares of the company’s stock, valued at $9,229,451.84. The trade was a 7.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Michael Gorley sold 64,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 30th. The stock was sold at an average price of $9.75, for a total transaction of $624,000.00. Following the transaction, the director directly owned 81,360 shares of the company’s stock, valued at $793,260. This represents a 44.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 406,199 shares of company stock valued at $3,718,977. 21.40% of the stock is currently owned by corporate insiders.

Institutional Trading of ASP Isotopes

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Marshall Wace LLP boosted its stake in shares of ASP Isotopes by 3,669.1% in the third quarter. Marshall Wace LLP now owns 1,279,121 shares of the company’s stock worth $12,305,000 after buying an additional 1,245,184 shares during the last quarter. Vanguard Group Inc. lifted its holdings in ASP Isotopes by 37.9% in the third quarter. Vanguard Group Inc. now owns 4,516,763 shares of the company’s stock valued at $43,451,000 after acquiring an additional 1,241,024 shares during the period. Jump Financial LLC purchased a new stake in ASP Isotopes in the 3rd quarter worth approximately $8,990,000. Squarepoint Ops LLC acquired a new stake in shares of ASP Isotopes during the 3rd quarter worth approximately $6,011,000. Finally, Invesco Ltd. increased its holdings in shares of ASP Isotopes by 2,205.0% during the 2nd quarter. Invesco Ltd. now owns 471,219 shares of the company’s stock valued at $3,468,000 after purchasing an additional 450,776 shares in the last quarter. Institutional investors and hedge funds own 16.80% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on ASPI shares. Weiss Ratings restated a “sell (e+)” rating on shares of ASP Isotopes in a research note on Thursday, October 30th. Canaccord Genuity Group reiterated a “buy” rating and issued a $11.00 target price on shares of ASP Isotopes in a report on Wednesday, September 17th. Finally, Loop Capital set a $15.00 price target on shares of ASP Isotopes in a research report on Monday, October 27th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $13.00.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.